Clinical Trials
740 trialsNCT04972097 2026-06-02
PRESERVE
Angiodynamics, Inc.
Phase NA Completed
NCT03910660 2026-05-15
A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.
BioXcel Therapeutics Inc
Phase 1/2 Completed
NCT06255041 2026-05-15
Detection of Cancer in Breath Samples by Trained Detection Dogs
SpotitEarly
Completed
NCT06604442 2026-05-12
Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy
Blue Earth Diagnostics
Phase 4 Completed
NCT01171898 2026-05-11
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)
Aragon Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT05114746 2026-05-08
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan
Novartis
Phase 2 Completed
NCT05005728 2026-05-05
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Xencor, Inc.
Phase 2 Completed
NCT07561502 2026-05-01
PERI III
Francis Medical Inc.
Phase NA Completed
NCT05177042 2026-04-28
Trial of ARV-110 and Abiraterone in Participants With Metastatic Prostate Cancer
Arvinas Inc.
Phase 1 Completed
NCT06104449 2026-04-27
MK-5684-005
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT04523207 2026-04-21
A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases
Janssen Research & Development, LLC
Phase 2 Completed
NCT05022849 2026-04-17
A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants
Janssen Research & Development, LLC
Phase 1 Completed
NCT04582656 2026-04-06
VIOLETTE
Koelis
Phase NA Completed
NCT06136598 2026-03-19
MK-5684-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT07477756 2026-03-19
A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients
Novartis
Completed
NCT05999968 2026-03-05
Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment
Eli Lilly and Company
Phase 1 Completed
NCT07450157 2026-03-04
A Study of Patient Characteristics, Treatment Patterns and Outcomes Among Patients Treated With 177Lu-PSMA-617
Novartis
Completed
NCT04736199 2026-02-27
ARANOTE
Bayer
Phase 3 Completed
NCT01314118 2026-02-24
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Janssen Biotech, Inc.
Phase 2 Completed
NCT06235099 2026-02-18
Solar-Recur
Curium US LLC
Phase 3 Completed
NCT04397276 2026-02-17
A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors
Janssen Research & Development, LLC
Phase 1 Completed
NCT03995888 2026-02-12
Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate Cancer
Blue Earth Diagnostics
Phase 1 Completed
NCT05701007 2026-01-29
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
Pfizer
Completed
NCT02003924 2026-01-27
PROSPER
Pfizer
Phase 3 Completed
NCT03338790 2026-01-27
CheckMate 9KD
Bristol-Myers Squibb
Phase 2 Completed
NCT03516110 2026-01-23
PRISME
Ipsen
Completed
NCT06840535 2026-01-06
OncoACP-3
Philogen S.p.A.
Phase 1 Completed
NCT06072196 2025-12-31
A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Pfizer
Completed
NCT02854436 2025-12-22
Galahad
Janssen Research & Development, LLC
Phase 2 Completed
NCT02985957 2025-12-22
CheckMate 650
Bristol-Myers Squibb
Phase 2 Completed
NCT04428788 2025-12-22
Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer
Celgene
Phase 1 Completed
NCT06055946 2025-12-22
BARVANA LONG
Aesculap AG
Completed
NCT00117286 2025-12-18
Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer
Ferring Pharmaceuticals
Phase 2/3 Completed
NCT04034095 2025-12-15
A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan
Janssen Pharmaceutical K.K.
Completed
NCT06462014 2025-12-11
Description of Relugolix Use in Patients With Prostate Cancer Within the VHA
Pfizer
Completed
NCT07086651 2025-12-08
A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC)
Pfizer
Completed
NCT01147965 2025-11-25
QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA
NantCell, Inc.
Phase 1/2 Completed
NCT02294461 2025-10-24
An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants
Astellas Pharma Inc
Phase 3 Completed
NCT04838613 2025-10-20
GuidePath
Novartis
Phase 3 Completed
NCT03939689 2025-10-14
ARROW
Progenics Pharmaceuticals, Inc.
Phase 2 Completed
NCT04560452 2025-10-08
Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese Patients
AstraZeneca
Completed
NCT04838626 2025-10-07
GuideView
Novartis
Phase 2/3 Completed
NCT04186845 2025-09-22
Spotlight
Blue Earth Diagnostics
Phase 3 Completed
NCT05323747 2025-09-16
BP-008
BioProtect
Completed
NCT05354427 2025-09-16
CLP-10095
BioProtect
Completed
NCT07014488 2025-09-10
A Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Oral HRS-5041 in Healthy Subjects
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT05590793 2025-09-09
Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate
Ipsen
Phase 3 Completed
NCT05946603 2025-09-04
IS-002 Phase 2 Prostate Cancer Study
Intuitive Surgical
Phase 2 Completed
NCT05605964 2025-08-17
Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT04553926 2025-08-14
OLAP
AstraZeneca
Completed